Lactocore Group

Exciting news! Our research team has published a groundbreaking study introducing a novel animal model for neuropharmacological studies. 🔬 We validated an associated learning paradigm using the cichlid fish species Maylandia callainos, which offers several advantages over the commonly used zebrafish model: ✅ Can be housed and tested individually, reducing stress ✅ Larger size allows for different drug administration routes ✅ Exhibits complex cognitive abilities suitable for learning and memory studies Our findings demonstrate that M. callainos can associate environmental cues (side and color) with rewards in a modified T-maze apparatus. Importantly, we showed that their behavior can be modulated by drugs like MK-801 and caffeine, widely studied in rodent and zebrafish models. The visually-cued operant conditioning task we developed allows for prolonged (over a week) dynamics of learning in fish, with sex-independent results and retained place preference for at least a week after training. Our research supports M. callainos as a viable and efficient model for preliminary drug screening experiments, enhancing the precision of advancing neuropharmacological investigations. Read the full article to dive deeper into our research and feel free to share your thoughts and engage in the discussion!🔬🐟 https://lnkd.in/eQc3tDzT #NeuroscienceResearch #AnimalModels #DrugScreening #LearningAndMemory #CichlidFish #Lactocore #Innovations

We are in the news again! In short, we have reported the unusual properties of a proprietary peptide, LCGA-17m16, aimed at treating psychiatric disorders without harming the heart. This signals a potential paradigm shift in the treatment of mental disorders. https://lnkd.in/eNg39nYw #Biotech #DrugDevelopment #PeptideTherapy #HeartHealth #AI

Lactocore Group with its AI-inhanced platform Reptide joins NVIDIA Inception to accelerate peptide therapeutics development! We are proud to announce that Lactocore Group is now a member of NVIDIA Inception, a program designed to nurture startups revolutionizing industries through technological advancements. This collaboration will enhance our capabilities in leveraging biotechnology for health improvements through the development of innovative peptides. Our focus remains on discovering and harnessing the therapeutic potential of peptides using structural bioinformatics and artificial intelligence. As part of NVIDIA Inception, Lactocore will gain access to technical training, preferred pricing on NVIDIA hardware/software, and specialized technology assistance. This will significantly boost our computational biology projects and facilitate our flagship anxiety treatment program's readiness for IND/CTA-enabling studies. This opportunity also opens doors for collaboration with industry-leading experts and other AI-driven organizations, which will undoubtedly enrich our insights and expedite our progress in developing next-generation peptide therapies. We look forward to utilizing these resources to their fullest potential, aiming to achieve substantial advancements in medical treatments and healthcare solutions. #Lactocore #NVIDIAInception #HealthcareInnovation #PeptideResearch #BiotechIndustry #MedicalScience #Reptide #AI

We're in biotech news with our Reptide AI platform, which discovered the LCGM-10 peptide. This peptide has emerged as a promising drug candidate for treating ADHD, OCD, and conditions related to impulsive behavior, such as drug addiction and gambling, all without the side effects associated with current therapies. https://lnkd.in/dkn2W8xE #AI #Reptide #Biotech #Innovation

On the occasion of National Pet Day, observed annually on April 11th, Lactocore takes this opportunity to highlight our dedicated efforts toward advancing pet health alongside human health initiatives. Our innovative research encompasses the development of milk peptide-based treatments aimed at addressing post-traumatic stress disorder (PTSD) and anxiety in domestic animals, an area of significant need within both veterinary and human medicine. The prevailing treatments for PTSD in veterinary practice are largely limited to a small range of antidepressants, with little to no advancements made in treatments specifically targeting this disorder. Lactocore is committed to changing this status quo. It is essential to understand that PTSD in pets does not manifest as constant emotional suppression, as it might in depressive disorders in humans. Rather, animals experience specific triggers that provoke abnormal behaviors. Our research is focused on developing treatments that can alleviate these triggers, offering relief and improving the quality of life for affected animals. Among the most prevalent anxiety-related issues in dogs are reactions to noise, separation, and transportation. The application of human medications to pets carries inherent risks of side effects, compounded by the inability of animals to communicate adverse reactions verbally. The development of safe, milk peptide-based medications represents a crucial advancement in this field. Lactocore employs scientifically validated models to assess drug efficacy on various behavioral indicators of anxiety, striving to ensure significant benefits for pets. As we commemorate National Pet Day, Lactocore reaffirms its dedication to expanding the scope of peptide applications, not only for common medical conditions but also for complex disorders where current treatment options are limited. #NationalPetDay #PetHealth #VeterinaryMedicine #PeptideResearch #InnovationInHealth #MilkPeptide

Can a milk-derived peptide serve as a safe alternative to gabapentinoids for treating mental  disorders? Gabapentinoids reduce the excitability of neurons in the brain, playing a crucial role in managing seizures and the transmission of pain signals. While these drugs are effective in alleviating epilepsy symptoms, nerve pain, and anxiety, they are associated with a range of side effects, including serious heart problems. Our latest research positions LCGA-17m16 peptide as a potential game-changer in the treatment of mental  disorders. Due to its unique structure, LCGA-17m16 precisely binds to the appropriate brain receptors without affecting the heart muscle tissue receptors. In other words, it can benefit the brain without impacting the heart! This represents another significant contribution by our  research team to the development of safer and more effective treatments for  mental  conditions. We are thrilled to share our breakthrough and eager to contribute to the revolution in patient care. #Neuroscience #BiotechInnovation #SaferMedications #LCGA17m16

We are pleased to announce that Lactocore's recent groundbreaking research on mGluR5 antagonists has been published in the esteemed peer-reviewed journal, Frontiers in Behavioral Neuroscience. This significant achievement underscores our commitment to advancing the field of neurological therapeutics through innovative science. Our research team, utilizing our advanced AI-driven platform, has successfully identified novel peptide-based drug candidates targeting mGluR5 receptors. These receptors are crucial in the pathology of numerous neurological conditions, including depression, movement disorders, Parkinson’s, Alzheimer’s, ADHD, and addiction, making them a critical target for the development of safer and more effective treatments. The study highlights the identification of four previously undiscovered peptides that bind to mGluR5 and modulate its activity in a non-competitive manner. This discovery was facilitated by rigorous structural bioinformatics analyses and validated through comprehensive experiments conducted in cell lines, zebrafish, and rodent models. Notably, one peptide, LCGM-10, exhibited significant stimulatory effects, surpassing those of caffeine without the associated rebound effects. These promising findings suggest that LCGM-10 warrants further exploration as a potential therapeutic option for ADHD, OCD, and other conditions characterized by impulsive behavior, such as drug addiction and gambling. The absence of the side effects commonly linked with current treatments highlights the potential of LCGM-10 to revolutionize patient care in these areas. Our focus on peptide-based therapeutics stems from their exceptional safety and tolerability profiles compared to traditional small molecules, reinforcing our dedication to discovering and developing treatments that not only address unmet medical needs but also improve the quality of life for those affected by neurological disorders. https://lnkd.in/dg8pNQKY     #Neuroscience #BiotechInnovation #PeptideTherapy #MentalHealthResearch #DrugDevelopment #ADHDAwareness #OCDResearch

Discover how milk bioactive peptides could revolutionize the fight against chronic inflammation and age-related metabolic disorders! #Peptides #Inflammation #BioTech https://lnkd.in/eFBJX9Jp

Lactocore Group is excited to announce a groundbreaking discovery in the field of longevity research. Our team has identified milk peptides capable of slowing down the aging process and addressing chronic inflammation. This breakthrough emerged from a comprehensive study using Nothobranchius fish, also known as killifish, highlighting the potential of milk peptides in extending life expectancy. Our year-long experiment with killifish, a species mirroring key aspects of human aging, showed remarkable effects of the peptide CHM-273S in enhancing lifespan and healthled. The treated fish showed a lifespan extension of 62%, surpassing the effects of known treatments like metformin. As we gear up for clinical trials, this discovery marks a significant milestone in our journey towards developing safer and more effective treatments for aging and related diseases. Follow us for more updates on this exciting journey into the future of health and longevity. #LactocoreGroup #LongevityResearch #BiotechInnovation #MilkPeptides #HealthcareBreakthrough

The time has arrived for us to be part of the next generation of healthcare innovation! Join us on the EIT Health Video On-demand platform to discover groundbreaking solutions set to transform European healthcare. Our commitment at Lactocore remains unwavering: we aim to revolutionize the treatment of anxiety with new safe peptide medicines and enhance lives with our innovative solutions. As we progress, we're filled with anticipation and hope to make it to the finals. Stay tuned for more updates as we push the boundaries of technology and healthcare forward! https://lnkd.in/eNC-NAXS #LactocoreGroup #EITCatapult #Lifesciences #Innovation #NewYear2024